CN112641894B - A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction - Google Patents
A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction Download PDFInfo
- Publication number
- CN112641894B CN112641894B CN202110069638.0A CN202110069638A CN112641894B CN 112641894 B CN112641894 B CN 112641894B CN 202110069638 A CN202110069638 A CN 202110069638A CN 112641894 B CN112641894 B CN 112641894B
- Authority
- CN
- China
- Prior art keywords
- group
- traditional chinese
- chinese medicine
- medicine composition
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000007160 gastrointestinal dysfunction Effects 0.000 title abstract description 10
- 230000037356 lipid metabolism Effects 0.000 title abstract description 7
- 230000001105 regulatory effect Effects 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 76
- 230000000968 intestinal effect Effects 0.000 claims abstract description 24
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 206010010774 Constipation Diseases 0.000 claims abstract description 8
- 241000723343 Cichorium Species 0.000 claims description 32
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 32
- 241000699670 Mus sp. Species 0.000 claims description 31
- 244000197580 Poria cocos Species 0.000 claims description 31
- 235000008599 Poria cocos Nutrition 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 13
- 230000004064 dysfunction Effects 0.000 claims description 5
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 claims description 3
- 229960001595 lincomycin hydrochloride Drugs 0.000 claims description 3
- 229960002983 loperamide hydrochloride Drugs 0.000 claims description 3
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 20
- 235000013376 functional food Nutrition 0.000 abstract description 7
- 206010012735 Diarrhoea Diseases 0.000 abstract description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 abstract 1
- 238000011047 acute toxicity test Methods 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000008991 intestinal motility Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 29
- 240000009022 Smilax rotundifolia Species 0.000 description 28
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 28
- 235000001188 Peltandra virginica Nutrition 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000009835 boiling Methods 0.000 description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 239000008101 lactose Substances 0.000 description 12
- 238000011084 recovery Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 7
- 102100025841 Cholecystokinin Human genes 0.000 description 7
- 101800001982 Cholecystokinin Proteins 0.000 description 7
- 102100021022 Gastrin Human genes 0.000 description 7
- 108010052343 Gastrins Proteins 0.000 description 7
- 101800002372 Motilin Proteins 0.000 description 7
- 102400001357 Motilin Human genes 0.000 description 7
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 7
- 229940107137 cholecystokinin Drugs 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 7
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical group CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000030136 gastric emptying Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 5
- 229960002297 fenofibrate Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 210000003736 gastrointestinal content Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 208000033041 Somatoform disorder gastrointestinal Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000013433 optimization analysis Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for regulating lipid metabolism and improving gastrointestinal dysfunction. The Chinese medicinal composition can be applied to medicaments, health-care products and functional foods for preventing and treating lipid metabolism disorder and gastrointestinal dysfunction. The lipid metabolism disorder of the present invention includes hyperlipidemia, hypertriglyceridemia and/or low density lipidemia, and the gastrointestinal dysfunction includes gastrointestinal absorption disorder, intestinal motility disorder and/or constipation or diarrhea caused by intestinal flora. The medicines of the traditional Chinese medicine composition belong to medicine and food dual-purpose medicines, and no obvious toxic or side effect is found in acute toxicity tests.
Description
Technical Field
The invention relates to a new traditional Chinese medicine combination for regulating lipid metabolism and improving intestinal functions by compatibility of chicory root, tuckahoe and glabrous greenbrier rhizome, belonging to the technical field of traditional Chinese medicines.
Background
Hyperlipidemia is a metabolic disorder caused by one or more abnormal blood lipid levels, and the clinical routine examination indexes comprise total cholesterol, triglyceride, low density lipoprotein and high density lipoprotein. In recent years, with the improvement of living standard, the intake of high fat food is increasing, and bad living habits such as exercise and smoking are lacking, so that the incidence of hyperlipidemia is increasing. Hyperlipidemia acts as an independent risk factor for various cardiovascular diseases. The incidence of cardiovascular and cerebrovascular diseases and the mortality rate are also increased year by year. Recent epidemiological research results indicate that the incidence of hyperlipidemia is rising year by year and is becoming younger. The rate of dyslipidemia of adults in China is 40.4%, and more than two fifths of adults in China are seriously affected by hyperlipidemia diseases. The burden of hyperlipemia diseases is continuously increased, the risk of cardiovascular and fatty liver diseases such as cerebral apoplexy, myocardial infarction, coronary heart disease and the like is increased, and the life health and the life quality of people are seriously damaged.
Gastrointestinal dysfunction is also called gastrointestinal neurosis and is manifested by dyspepsia, constipation or diarrhea, and the pathogenesis of the gastrointestinal dysfunction is not known uniformly at present. Along with the improvement of living standard and working pressure, the incidence of gastrointestinal diseases related to gastrointestinal dysfunction is continuously increased, and emotions, diet and the like can induce or aggravate the disease condition, relate to people of all ages, and have serious influence on the living quality. And specific drugs are not available clinically for treating gastrointestinal dysfunction.
The chicory root, the tuckahoe and the glabrous greenbrier rhizome are all traditional Chinese medicinal materials with longer medicinal and edible histories, and have high safety. Chicory root and tuckahoe are the species recorded in the list of articles which are both food and medicine and published by the ministry of health, and glabrous greenbrier rhizome is listed in the list of articles which can be used for health food.
The chicory root has the effects of clearing liver, benefiting gallbladder, strengthening spleen, eliminating dampness, clearing heat and reducing swelling; the tuckahoe has the effects of promoting diuresis, eliminating dampness, strengthening spleen and calming heart; glabrous greenbrier rhizome, rhizoma Smilacis Glabrae is used for removing toxic substance and promoting diuresis. The subject combines the traditional medicine application and the modern pharmacological research, the chicory root, the tuckahoe and the glabrous greenbrier rhizome are combined and compatible, the traditional Chinese medicine composition is considered to be capable of regulating the lipid metabolism of the organism and improving the intestinal dysfunction, and the pharmacological action of the traditional Chinese medicine composition has the advantages of multiple ways and multiple targets. Further intensive research can develop the health care product, the medicine, the functional food and the like with the functions of reducing fat, losing weight, relaxing bowels, regulating intestinal functions and relevant functions.
Disclosure of Invention
The invention provides a new combination of traditional Chinese medicines, which is applied to medicines and health products for preventing and treating lipid metabolism disorder and improving diseases related to gastrointestinal dysfunction.
The traditional Chinese medicine of the invention comprises: 9-18 parts of chicory root, 10-15 parts of poria cocos and 15-60 parts of rhizoma smilacis glabrae.
Preferably, the traditional Chinese medicine composition of the invention comprises: 12-17 parts of chicory root, 10-12 parts of tuckahoe and 25-40 parts of glabrous greenbrier rhizome.
Further preferably, the traditional Chinese medicine composition of the invention comprises: 15 parts of chicory root, 10 parts of tuckahoe and 30 parts of glabrous greenbrier rhizome.
The invention provides application of the traditional Chinese medicine composition in preparing medicines, health-care products and functional foods with the effect of reducing blood fat.
The invention provides application of the traditional Chinese medicine composition in preparation of medicines, health-care products and functional foods with weight-losing efficacy.
The invention provides application of the traditional Chinese medicine composition in preparing medicines, health-care products and functional foods for treating intestinal dysfunction and/or constipation.
The invention provides application of the traditional Chinese medicine composition in preparing medicines, health-care products and functional foods for promoting intestinal peristalsis.
The invention provides application of the traditional Chinese medicine composition in preparing medicines, health-care products and functional foods for regulating intestinal flora.
The chicory root is the dry root of compositae plant Cichorium hirsutum Candidulosum Boiss.et Huet or Cichorium intybus L. Slightly bitter, salty and cool. It enters liver, gallbladder and stomach meridians. Clearing liver-fire and promoting bile flow; strengthening stomach and promoting digestion; induce diuresis to alleviate edema. Jaundice due to damp-heat pathogen; stomach ache and poor appetite; edema and oliguria.
The Poria cocos is dried sclerotium of Wolf of Poria cos (Schw.) Wolf, a fungus of Polyporaceae. Sweet, bland and mild in taste. It enters heart, lung, spleen and kidney meridians. Clearing damp and promoting diuresis; invigorating spleen; and (4) calming the heart. Edema and oliguria are predominant; phlegm-fluid retention with dizziness and palpitation; poor appetite due to spleen deficiency; diarrhea due to loose stool; uneasiness of the heart; palpitations and insomnia.
The glabrous greenbrier rhizome is a dried rhizome of Smilax glabra Roxb. Sweet, bland and mild in taste. It enters liver and stomach meridians. Detoxification; dehumidifying; and (6) passing through the links. The spasm of limbs caused by syphilis and mercury poisoning; muscle and bone pain; drenching turbid damp heat; leucorrhea; abscess and swelling; scrofula; scabies and tinea.
The research takes WR-1339-induced hyperlipidemia mouse model, loperamide hydrochloride-induced constipation mouse model and lincomycin hydrochloride-induced intestinal flora disorder mouse as experimental objects, and researches the influence of the traditional Chinese medicine composition on lipid metabolism level, intestinal peristalsis function and intestinal flora structure ratio. The clinical total effective rate reaches more than 85 percent, and the blood fat improving effect is better when the composition is matched with statin lipid-lowering drugs. No obvious adverse reaction occurs in all cases.
Drawings
FIG. 1 shows the stool morphology of the constipated mice in each group.
The following experimental examples and examples are intended to further illustrate the present invention.
Experimental example 1 Effect of Chinese medicinal composition on lipid metabolism level of hyperlipidemic mouse
1. Medicine and food additive
The traditional Chinese medicine composition water extract of chicory root, tuckahoe and glabrous greenbrier rhizome, brown liquid, and the dosage of each component is as follows: 15g of chicory root, 10g of tuckahoe and 30g of glabrous greenbrier rhizome.
2. Method of producing a composite material
Kunming mouse, male, weight 18-22 g. The body weights were randomly divided into a normal group, a model group, a positive drug fenofibrate group, a traditional Chinese medicine combination high dose group, and a traditional Chinese medicine combination low dose group. The normal group and the model group are injected with gastric distilled water, the other groups of animals are given with the corresponding drug for 7d, 1 time per day, 16 hours before the last administration, the normal group is injected with normal saline (10ml/kg) in the abdominal cavity, and the other groups are injected with 5% Trition WR-1339 in the abdominal cavity with the same volume to induce the hyperlipidaemia mouse model. 1h after the last administration, blood is taken from the eyeball, centrifuged at 3000 rpm, serum is separated, and the levels of Total Cholesterol (TC), Triglyceride (TG), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C) in the serum are detected. The experimental results are as follows:
(1) the effect on serum blood lipid (TC, TG, HDL-C, LDL-C) levels in hyperlipidemic mice is shown in Table 1.
in comparison with the normal group,*P<0.05,**P<0.01; in comparison to the set of models,#P<0.05,##P<0.01。
the results show that the serum TC, TG and LDL-C levels of the model group mice are obviously increased (P <0.01) and the HDL-C level is obviously reduced (P <0.01) compared with the normal group. Compared with the model group, the serum TG and LDL-C levels of the fenofibrate group are obviously reduced (P <0.05), the serum TG level of the high-dose group is obviously reduced (P <0.05), and the serum LDL-C level of the low-dose group is obviously reduced (P < 0.01). The experiment result 1 shows that the high dosage of the traditional Chinese medicine composition can obviously reduce the serum TG level of the hyperlipidemic mouse, and the low dosage of the traditional Chinese medicine composition can obviously reduce the LDL-C level of the hyperlipidemic mouse. The high-dose traditional Chinese medicine composition has the function of assisting in reducing the blood fat and the triglyceride, and the low-dose traditional Chinese medicine composition has the function of assisting in reducing the blood fat and the low-density lipoprotein. The small compound prescription with different dosages has different degrees of treatment effect on the hyperlipoidemia.
(2) The results of the effects on the body weight of the hyperlipidemic mice are shown in Table 2.
group of | Example number (n) | Body weight |
Normal group | 10 | 28.62±0.94 |
Model set | 10 | 28.43±0.98 |
Fenofibrate group | 10 | 28.52±1.08 |
High-dose group of traditional Chinese medicine composition | 10 | 28.10±1.21 |
Low-dose group of traditional Chinese medicine composition | 10 | 28.83±1.11 |
The results show that no obvious difference is found in body weight among groups, and the animals in each group have good growth condition and good hair color spirit during the experiment.
Experimental example 2 Effect of Chinese medicinal composition on Constipation gastrointestinal function of mice
1. Medicine and food additive
The traditional Chinese medicine composition water extract of chicory root, tuckahoe and glabrous greenbrier rhizome, brown liquid, and the dosage of each component is as follows: 15g of chicory root, 10g of tuckahoe and 30g of glabrous greenbrier rhizome.
2. Method of producing a composite material
Half of Kunming mouse, 18-22 g. The weight of the composition is randomly divided into a normal group, a model group, a positive drug mosapride group, a traditional Chinese medicine combination high-dose group and a traditional Chinese medicine combination low-dose group, and each group contains 12 drugs. Except for normal groups, each group of animals is perfused with 0.4ml of loperamide hydrochloride capsules (10mg/kg) for 1 time per day for 3 days continuously, and a slow-transit constipation mouse model is shaped, so that the model success standard is determined by that mice have hypokinesia, curl, slow movement, obvious hardened and small excrement and water content obviously reduced by naked eyes. After 3d of modeling, the positive group of mice is intragastrically administered with Mosapride citrate (2.25mg/kg), and the observation group is intragastrically administered with a small compound; the mice in the normal group and the model group are infused with physiological saline with the same volume, and the infusion administration interval of the molding and the intervention is 30min and is continued for 6 days.
After 0.5h of the last administration, 0.25mL of 0.05% phenol red paste prepared from 1.5% cmc-Na was injected into each mouse, the eyeball was removed after 20min, blood serum was separated at 3000 rpm, and the levels of MTL (motilin), GAS (gastrin), and CCK (cholecystokinin) in the blood serum were measured. The stomach and small intestine of the mouse were removed, the stomach was cut open by stretching the greater curvature of the stomach, the contents were washed in a test tube with 4mL of distilled water, the residue was vortexed for 3min, centrifuged at 3500r/min for 10min, and the gastric emptying rate was measured. Simultaneously ligating the lower end of the pylorus and the cardia part, taking out the intestinal tract from the cardia to the tail end of the rectum, separating the pylorus, measuring the total length of the small intestine and the distance from the phenol red front to the pylorus, and calculating the intestinal propulsion rate.
(1) The effect of the combination of Chinese herbs on the gastric emptying rate of constipated mice is shown in Table 3.
group of | Gastric emptying rate (%) |
Normal group | 0.68±0.08 |
Model set | 0.46±0.08* |
Mosapride group | 0.51±0.05 |
High-dose group of traditional Chinese medicine composition | 0.55±0.05## |
Traditional Chinese medicine composition low-dose group | 0.53±0.06# |
In comparison with the normal group,*P<0.01. in comparison to the set of models,#P<0.05,##P<0.01。
during the experiment, the gastric emptying rate was significantly reduced in the model group compared to the normal group (P < 0.01). After the last administration, the gastric emptying rate of the high-dose and low-dose groups is obviously improved (P <0.01 or P < 0.05).
(2) The effect of the combination of Chinese herbs on intestinal transit in constipated mice is shown in Table 4.
group of | Example number (n) | Small intestine propulsion ratio (%) |
Normal group | 14 | 0.64±0.17 |
Model set | 16 | 0.39±0.10* |
Mosapride group | 16 | 0.46±0.11 |
High-dose group of traditional Chinese medicine composition | 16 | 0.54±0.19## |
Low-dose group of traditional Chinese medicine composition | 16 | 0.52±0.13## |
In comparison with the normal group,*P<0.01. in comparison to the set of models,##P<0.01。
during the experiment, the small intestine propulsion rate was significantly reduced in the model group compared to the normal group (P < 0.01). After the last administration, the small intestine propulsion rate of the high-dose and low-dose groups is obviously improved (P < 0.01).
(3) The effect of the combination of Chinese herbs on the gastrointestinal hormone levels of constipated mice, the results are shown in Table 5.
group of | MTL | GAS | CCK |
Normal group | 37.01±7.0 | 5.67±2.20 | 55.86±7.02 |
Model set | 32.86±8.22 | 5.40±2.17 | 60.38±6.03 |
Mosapride group | 35.34±8.26 | 6.72±3.05 | 52.68±6.17## |
High-dose group of traditional Chinese medicine composition | 34.36±5.04 | 6.48±3.05 | 50.92±8.02## |
Low-dose group of traditional Chinese medicine composition | 34.91±7.62 | 6.26±2.83 | 53.38±4.44## |
In comparison to the set of models,##P<0.01。
during the experiment, compared with the normal group, the serum MTL and GAS levels of the model group are reduced, and the serum CCK level is increased. Compared with the model group, the serum MTL and GAS levels of the mosapride group are increased, and the serum CCK level is obviously reduced (P < 0.01); the serum MTL and GAS levels of the high and low dose groups of the traditional Chinese medicine composition tend to be increased, and the serum CCK level is obviously reduced (P < 0.01).
(4) The effect of the combination of Chinese herbs on the stool morphology of the constipated mice is shown in figure 1.
Compared with the feces of the normal group of mice, the feces of the model group have hardened texture, reduced volume and rough surface; compared with the feces of mice in a model group, the feces of each treatment group have softer texture, large volume and smooth surface.
Experimental example 3 influence of Chinese medicinal composition on intestinal flora-related indicators of mice with intestinal flora disturbance
1. Medicine and food additive
The traditional Chinese medicine composition water extract of chicory root, tuckahoe and glabrous greenbrier rhizome, brown liquid, and the dosage of each component is as follows: 15g of chicory root, 10g of poria cocos and 30g of rhizoma smilacis glabrae.
2. Method of producing a composite material
Kunming mouse, male, 18-22 g. The weight of the composition is randomly divided into a normal group, a natural recovery group, a positive drug bacillus subtilis dual viable bacteria particle group, a traditional Chinese medicine combination high dose group and a traditional Chinese medicine combination low dose group, and each group contains 8 active ingredients. Except for normal groups, animals of each group are perfused with lincomycin hydrochloride (300mg/ml)0.3ml 2 times a day for 3 days continuously, and mice models with intestinal flora disorder are shaped. And (4) performing intragastric administration of distilled water to animals in the normal group and the natural recovery group, and administering corresponding medicines to the other animals in each group for 7 days continuously. After 1h of the last administration, the eyes were removed and blood was collected, serum was separated at 3000 rpm, and Total Protein (TP), albumin, immunoglobulin G (IgG) levels in the serum were measured. Spleens were isolated, weighed, and spleen index calculated. Collecting small intestine mucus, and detecting secretory immunoglobulin A (sIgA) level. Collecting cecal contents, inoculating bacterial liquid diluted in a proper proportion into a plate paved with a corresponding culture medium, carrying out inverted culture in a biochemical incubator at 37 ℃ for 24-48h, identifying bacterial count, and calculating the colony formation number of each bacterial colony in bacterial liquid per milliliter.
(1) The results of the effects on spleen index in mice with disturbed intestinal flora are shown in Table 6.
group of | Spleen index |
Normal group | 0.37±0.002 |
Model set | 0.37±0.001 |
Bacillus subtilis dual viable bacteria granule group | 0.34±0.001 |
High-dose group of traditional Chinese medicine composition | 0.36±0.001 |
Low-dose group of traditional Chinese medicine composition | 0.38±0.001 |
The results showed no significant change in spleen index for each group of mice.
(2) The results of the effects on TP, albumin, IgG and sIgA levels of mice with disturbed intestinal flora are shown in Table 7.
group of | TP(μg/mL) | Albumin (g/L) | IgG(g/L) | sIgA(μg/mL) |
Normal group | 75115.34±7394.71 | 28.64±3.30 | 0.0022±0.0002 | 9.58±0.82 |
Natural recovery group | 60821.33±13397.48* | 28.08±7.44 | 0.0022±0.0002 | 8.62±0.63* |
Bacillus subtilis dual viable bacteria granule group | 75319.74±12696.10# | 27.57±4.41 | 0.0023±0.0001 | 8.76±0.66 |
High-dose group of traditional Chinese medicine composition | 75071.53±16470.50 | 30.63±2.83 | 0.0023±0.0001 | 8.58±0.51 |
Low-dose group of traditional Chinese medicine composition | 70808.15±19538.87△ | 33.37±3.92△ | 0.0024±0.0003 | 8.86±0.38 |
In comparison with the normal group,*P<0.05; in contrast to the natural recovery group,#P<0.05;△P<0.1。
compared with the normal group, the serum TP and intestinal mucus sIgA levels of the mice in the natural recovery group are obviously reduced (P < 0.05). Compared with the natural recovery group, the serum TP and albumin levels of the traditional Chinese medicine combination high-dose group tend to be increased (P is 0.07).
(3) The results of the effects on the number of four main host bacteria in the intestinal tract of mice with disturbed intestinal flora are shown in Table 8.
TABLE 8 intestinal content of each group of mice four major host colony culture counts (CFU/mL, n 8, x + -s)
Group of | Escherichia coli | Enterococcus | Bifidobacterium | Lactobacillus strain |
Normal group | 5.92±0.19 | 6.03±0.18 | 8.38±0.17 | 7.98±0.15 |
Natural recovery group | 8.16±0.19** | 7.99±0.24** | 8.24±0.12 | 7.96±0.08 |
Bacillus subtilis dual viable bacteria granule group | 7.37±0.11## | 7.45±0.11## | 8.55±0.15## | 7.86±0.27 |
High-dose group of traditional Chinese medicine composition | 7.16±0.19## | 7.20±0.25## | 8.29±0.10 | 7.98±0.17 |
Low-dose group of traditional Chinese medicine composition | 7.16±0.31## | 7.36±0.34## | 8.01±0.22## | 7.79±0.12** |
In comparison with the normal group,**P<0.01; in contrast to the natural recovery group,##P<0.01。
compared with the normal group, the serum TP and intestinal mucus sIgA levels of the mice in the natural recovery group are obviously reduced (P < 0.05). Compared with the natural recovery group, the serum TP and albumin levels of the traditional Chinese medicine combination high-dose group tend to be increased (P is 0.07). Compared with the normal group, the amount of Escherichia coli and enterococcus bacteria in the mice in the natural recovery group is obviously increased after the intestinal content is cultured (P < 0.01). Compared with a natural recovery group, the bacillus subtilis dual viable bacteria granular group mouse and the traditional Chinese medicine combined high-dose and low-dose group mouse have obviously reduced escherichia coli and enterococcus bacteria content after the intestinal content is cultured (P is less than 0.01); the amount of the bifidobacterium and lactobacillus in the low-dose group of the traditional Chinese medicine composition is obviously reduced.
Experimental example 4 optimization analysis of Chinese medicinal composition for hyperlipidemia mice
1. Medicine and food additive
The formula 1 is as follows: 15g of chicory root, 10g of tuckahoe and 30g of glabrous greenbrier rhizome;
and (2) formula: 10g of chicory root, 15g of tuckahoe and 20g of glabrous greenbrier rhizome;
and (3) formula: 15g of chicory root, 20g of tuckahoe and 50g of glabrous greenbrier rhizome.
Each prescription is boiled and extracted by water, and is concentrated into brown liquid with the weight volume ratio of 1: 1.
2. Method of producing a composite material
Kunming mouse, male, weight 18-22 g. The weights of the patients are randomly divided into a normal group, a model group, a fenofibrate group, a formula 1 group, a formula 2 group and a formula 3 group. The normal group and the model group are injected with gastric distilled water, the other groups of animals are given with the corresponding drug for 7d, 1 time per day, 16 hours before the last administration, the normal group is injected with normal saline (10ml/kg) in the abdominal cavity, and the other groups are injected with 5% Trition WR-1339 in the abdominal cavity with the same volume to induce the hyperlipidaemia mouse model. 1h after the last administration, blood is taken from the eyeball, centrifuged at 3000 rpm, serum is separated, and the levels of Total Cholesterol (TC), Triglyceride (TG), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C) in the serum are detected. The experimental results are as follows:
(1) the effects on serum blood lipid (TC, TG, HDL-C, LDL-C) levels in hyperlipidemic mice are shown in Table 9.
in comparison with the normal group,*P<0.05,**P<0.01; in comparison to the set of models,#P<0.05,##P<0.01。
the results show that the serum TC, TG and LDL-C levels of the model group mice are obviously increased (P <0.01) and the HDL-C level is obviously reduced (P <0.01) compared with the normal group. Compared with the model group, the serum TG and LDL-C levels of the fenofibrate group are obviously reduced (P < 0.05); the TG and LDL-C levels of the formula 1 group are obviously reduced (P is less than 0.05); and the effects of the compositions 2 and 3 are not obvious. The experimental results show that the group 1 can significantly reduce the serum TG and LDL-C levels of the mice with hyperlipidemia, and the group 1 (namely the composition of 15 parts by mass of chicory root, 10 parts by mass of tuckahoe and 30 parts by mass of glabrous greenbrier rhizome) is better in effect of reducing the blood fat.
Detailed Description
Example 1:
9-18g of chicory root, 10-15g of tuckahoe, 15-60g of glabrous greenbrier rhizome, boiling and extracting for 2 times by 10 times of hot water, each time for 90min, merging boiling and extracting solutions, and concentrating to obtain an extract.
Auxiliary materials: lactose
Adding lactose into the above extract, and making into granule by conventional method.
Example 2:
9-18g of chicory root, 10-15g of tuckahoe, 15-60g of glabrous greenbrier rhizome, boiling and extracting for 2 times by 10 times of hot water, each time for 90min, merging boiling and extracting solutions, and concentrating to obtain an extract.
Auxiliary materials: lactose
Adding lactose and CMC-Na into the above extract, and making into oral liquid or functional beverage by conventional method.
Example 3:
9-18g of chicory root, 10-15g of tuckahoe, 15-60g of glabrous greenbrier rhizome, boiling and extracting for 2 times by 10 times of hot water, each time for 90min, merging boiling and extracting solutions, and concentrating to obtain an extract.
Auxiliary materials: lactose
Adding lactose and CMC-Na into the above extract, making into granule by conventional method, and making into capsule.
Example 4:
9-18g of chicory root, 10-15g of tuckahoe and 15-60g of glabrous greenbrier rhizome, wherein the extract is obtained by boiling and extracting for 2 times by 10 times of hot water for 90min each time, merging the boiling and extracting solutions and concentrating to obtain an extract.
Auxiliary materials: starch
Adding starch into the above extract, and making into capsule by conventional method.
Example 5:
9-18g of chicory root, 10-15g of tuckahoe, 15-60g of glabrous greenbrier rhizome, boiling and extracting for 2 times by 10 times of hot water, each time for 90min, merging boiling and extracting solutions, and concentrating to obtain an extract.
Auxiliary materials: dextrin
Adding dextrin into the above extract, and making into capsule by conventional method.
Example 6:
9-18g of chicory root, 10-15g of tuckahoe and 15-60g of glabrous greenbrier rhizome, wherein the extract is obtained by boiling and extracting for 2 times by 10 times of hot water for 90min each time, merging the boiling and extracting solutions and concentrating to obtain an extract.
Auxiliary materials: sorbitol
Adding sorbitol into the above extract, and making into capsule by conventional method.
Example 7:
15g of chicory root, 10g of tuckahoe and 30g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: lactose
Adding lactose into the above extract, and making into granule by conventional method.
Example 8:
12g of chicory root, 12g of tuckahoe and 35g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: lactose
Adding lactose and CMC-Na into the above extract, and making into oral liquid or functional beverage by conventional method.
Example 9:
16g of chicory root, 11g of tuckahoe and 25g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: lactose
Adding lactose and CMC-Na into the above extract, making into granule by conventional method, and making into capsule.
Example 10:
14g of chicory root, 10g of tuckahoe and 40g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: starch
Adding starch into the above extract, and making into capsule by conventional method.
Example 11:
13g of chicory root, 15g of tuckahoe and 30g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: dextrin
Adding dextrin into the above extract, and making into capsule by conventional method.
Claims (7)
1. A traditional Chinese medicine composition for preventing and treating hyperlipidemia and intestinal dysfunction is characterized by being prepared from 15 parts by weight of chicory root, 10 parts by weight of poria cocos and 30 parts by weight of rhizoma smilacis glabrae.
2. The traditional Chinese medicine composition of claim 1, wherein the traditional Chinese medicine composition is added with pharmaceutically or physiologically acceptable auxiliary materials to prepare an application preparation.
3. Use of the Chinese medicinal composition according to claim 1 for the preparation of a medicament for the treatment of hyperlipidemia or intestinal dysfunction.
4. Use according to claim 3, wherein the intestinal dysfunction comprises constipation or intestinal flora disorders.
5. The use of claim 3, wherein the hyperlipidemia is caused by 5% Trition WR-1339 induced mice.
6. The use of claim 4, wherein the constipation is caused by induction of mice with loperamide hydrochloride.
7. The use according to claim 4, wherein the intestinal flora disturbance is caused by the induction of mice with lincomycin hydrochloride.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020100598792 | 2020-01-19 | ||
CN202010059879 | 2020-01-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112641894A CN112641894A (en) | 2021-04-13 |
CN112641894B true CN112641894B (en) | 2022-06-17 |
Family
ID=75370565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110069638.0A Active CN112641894B (en) | 2020-01-19 | 2021-01-19 | A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112641894B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115300586B (en) * | 2021-08-09 | 2023-10-10 | 北京中医药大学 | Traditional Chinese medicine composition for resisting urate renal deposition and preparation method thereof |
CN115715782B (en) * | 2021-08-24 | 2023-12-26 | 北京中医药大学 | Traditional Chinese medicine composition for preventing and treating ulcerative colitis and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103463531A (en) * | 2013-09-27 | 2013-12-25 | 张清峰 | Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods |
CN109748981A (en) * | 2017-11-02 | 2019-05-14 | 中国科学院微生物研究所 | A kind of alkali carries method and its application of pachymaran |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101791383A (en) * | 2010-01-06 | 2010-08-04 | 崔晓廷 | Compound chicory series product and effect of adjusting blood sugar, blood fat and blood uric acid |
-
2021
- 2021-01-19 CN CN202110069638.0A patent/CN112641894B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103463531A (en) * | 2013-09-27 | 2013-12-25 | 张清峰 | Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods |
CN109748981A (en) * | 2017-11-02 | 2019-05-14 | 中国科学院微生物研究所 | A kind of alkali carries method and its application of pachymaran |
Non-Patent Citations (1)
Title |
---|
菊苣提取物对腹型肥胖大鼠肠道菌群的影响;孙博喻等;《中国中药杂志》;20140630;第39卷(第11期);第2081-2085页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112641894A (en) | 2021-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048933B (en) | Chinese medicinal composition for treating infantile diarrhea and preparation method thereof | |
CN107496850B (en) | It is a kind of adjust enteral microecological formulation formula and application | |
CN110787233B (en) | Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof | |
CN112641894B (en) | A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction | |
CN102198262A (en) | Chinese medicine preparation for treating infant rotavirus enteritis and preparation method thereof | |
CN114470114B (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
CN108434242A (en) | A kind of pharmaceutical composition, preparation method and its usage for treating diabetes and its complication | |
CN108785594A (en) | A kind of Chinese herbal ointment formula and preparation method for intervening phlegm-dampness constitution | |
CN112826889A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease | |
CN107412713A (en) | Treat Chinese patent drug, dietetic food and the preparation method of autoimmune and immune related diseases | |
CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
CN115252737A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease, preparation method and application | |
CN111375004B (en) | Traditional Chinese medicine enema for treating non-alcoholic steatohepatitis and preparation method and application method thereof | |
CN114191515A (en) | Oral gel for dispelling dampness, invigorating stomach and improving immunity and preparation method thereof | |
CN114158735A (en) | Probiotic composition and application thereof | |
CN103720808B (en) | A kind of composition and use thereof, preparation method with relieving constipation effect | |
CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
CN105796821A (en) | Composition for removing food retention and relaxing bowels, preventing gastrointestinal cold and boosting immunity in children | |
CN104707126A (en) | Medicament for treating streptococcus pneumonia infected pneumonia and preparation method thereof | |
CN110420297A (en) | A kind of Chinese materia medica preparation for anti-trioxypurine | |
CN116370592B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver fibrosis as well as preparation method and application thereof | |
CN108771658A (en) | A kind of bowel relaxing oral liquid and preparation method | |
CN104324209B (en) | One kind treats snorting Chinese medicine composition of pig and preparation method thereof | |
CN116832101B (en) | Traditional Chinese medicine composition, preparation and application for treating spleen and stomach damp-heat syndrome of Hp related dyspepsia | |
CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |